News

On January 9, 2014, Avillion announced it had entered into an exclusive collaborative development agreement with Pfizer Inc. to conduct a global Phase 3 clinical trial of BOSULIF.

The patent describes and claims a targeted drug delivery method that combines bacterial minicells and a "bispecific ligand" in a composition lacking undesirable contamination from parent bacterial cells

This approval represents the first ADASUVE approval in Latin America for Ferrer and Alexza. Ferrer is Alexza’s commercial partner for ADASUVE in the EU, Latin America and Commonwealth

This syringe technology developed under its product name "ChaSyr," (pronounced chaser), allows for the sequential administration of two separate intravenous (IV) medications with a single syringe, replacing multiple

The new initiative will help restart dosing of medication for patients who participated in previous clinical studies of exon skipping drugs – a promising approach to the disease

Originally discovered and developed by Infinity Pharmaceuticals, the fatty acid amide hydrolase (FAAH) inhibitor has already been tested in the clinic in healthy volunteers and will be studied

The application covers InVivo’s Neuro-Spinal Scaffold, which is currently being studied in a pilot clinical trial, and its Neuro-Spinal Scaffold combined with stem cells, which is being developed

Polymyositis and dermatomyositis are rare inflammatory myopathies that cause inflammation and progressive weakness in muscles. As part of the deal, the two firms will develop educational programs and

The company said that data from its pilot phase IIa efficacy study in adult ADHD showed efficacy in a range similar to stimulants. The new trial will assess